ONMD ONEMEDNET CORP

OneMedNet Delivers on Revenue Model Promise with Palantir-Powered RWD Subscriptions: Live Feeds & AI Search

OneMedNet Delivers on Revenue Model Promise with Palantir-Powered RWD Subscriptions: Live Feeds & AI Search

MINNEAPOLIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-empowered Real-World Data (RWD), today announced that it will demonstrate its next-generation iRWD™ platform at ISPOR Europe. Built on the Palantir Technologies Foundry ecosystem, the platform enables life sciences, diagnostics, and medical device organizations to securely generate and analyze regulatory-grade, de-identified real-world data (RWD) through advanced AI-driven analytics.

Earlier this year, OneMedNet advanced its strategy by introducing a recurring revenue model designed to simplify and streamline customer access to high-value RWD, powered by Palantir’s Foundry and AIP, the iRWD™ subscription model features two innovative offerings: Live Data Feeds and AI-Driven Conversational Search. These enhancements convert traditional static data access into dynamic, on-demand intelligence, allowing customers to continuously harness regulatory-grade, multimodal data for real-time insights, accelerated decision-making, and deeper engagement. This approach not only bolsters OneMedNet’s recurring revenue foundation but has already generated significant market interest.

  • Live Data Feeds deliver ongoing, real-time streams of de-identified clinical data, enabling organizations to monitor trends, respond to emerging needs, and integrate fresh insights seamlessly into their workflows.
  • AI-Driven Conversational Search allows users to query complex datasets using natural language, with the platform’s deep clinical understanding interpreting intent to build precise cohorts without requiring rigid search strings. This democratizes data access, reduces technical barriers, and accelerates innovation by making sophisticated analytics intuitive and efficient.

As the healthcare sector reaches a transformative inflection point, the AI-enabled market presents an estimated US$868 billion1 opportunity by 2030, according to research from Strategy&, a PwC brand. Yet, a key challenge persists: securing high-quality, timely, de-identified clinical multimodal data. As highlighted in OneMedNet's recent announcement of its selection to utilize Palantir's platforms, "responsible access to healthcare data remains a key barrier" to unlocking this crucial opportunity."

“We’re excited about the future as we continue to execute upon our strategy. Palantir’s Foundry and AIP platform supercharge our ability to deliver regulatory-grade, multimodal RWD with unparalleled speed, consistency, traceability, and security,” said Aaron Green, President and CEO of OneMedNet. “Our iRWD™ platform marks a significant leap forward in how life sciences and AI innovators discover, access, and operationalize real-world data from vast clinical datasets. Together with Palantir, we’re showcasing a revolutionary conversational search tool that deeply understands clinical nuances, enabling end users to pinpoint precise datasets effortlessly. This AI-powered approach to cohort building will transform the clinical data acquisition landscape!”

  1.   



About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,750 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at .

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. We base these forward-looking statements on our current expectations and projections about future events, which we derive from the information presently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin’s volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.

OneMedNet Contacts:

Michael Wong, VP Marketing

Email:  



EN
10/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONEMEDNET CORP

 PRESS RELEASE

OneMedNet Announces Next Phase of Commercial Launch with its Real-Worl...

OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively c...

 PRESS RELEASE

OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale,...

OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a digital health company specializing in autoimmune disease populations. This partnership expands OneMedNet’s autoimmune clinical ontology, to the OneMedNet iRWD™ platform—powered by Palantir Foundry—further increasing the scale, diversity, an...

 PRESS RELEASE

OneMedNet Announces Strategic Neuro Data Partnership with Risorius to ...

OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms for central nervous system (CNS) indications across neurology, psychiatry, and sleep. This new relationship supports OneMedNet’s continued focus on expan...

 PRESS RELEASE

OneMedNet Reports Record 2025 Bookings of $2.79 Million, Surpassing Pr...

OneMedNet Reports Record 2025 Bookings of $2.79 Million, Surpassing Prior Year by More Than 4.1X and Accelerating Subscription Transition MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), today announced record bookings in 2025 of data-delivery agreements totaling $2.79 million of contract value, exceeding 2024 bookings by more than four times (4X). The milestone reflects increasing deal size, strong enterprise demand, and meaningful progress toward a recurring...

 PRESS RELEASE

OneMedNet Real-World Data Supports FDA 510(k) Clearance of AI-Powered ...

OneMedNet Real-World Data Supports FDA 510(k) Clearance of AI-Powered Scaida BrainCT-ICH Software MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced that its high-quality, multimodal clinical data supported mlHealth 360 in obtaining U.S. Food and Drug Administration (FDA) 510(k) clearance for Scaida BrainCT-ICH, an AI-powered software solution designed to facilitate the rapid detection of intracranial hemorrhage (ICH) from head computed tomography (CT) scans. Scaida B...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch